Umbilical cord derived mesenchymal stem cells therapy in hypoxic ischaemic encephalopathy
Overview:
This phase 1 study is being conducted at the First Hospital of Hebei
Medical University, where researchers are evaluating the safety and
effectiveness of umbilical cord derived mesenchymal stem cells
(MSC’s) in the treatment of hypoxic ischaemic encephalopathy brain
injury.
Ten patients are given an intravenous infusion of umbilical cord blood stem cells at the same time. All patients will be evaluated before and after treatment for 15 days, 90 days and 180 days respectively for the curative effect. The study commenced in 2013 and the estimated completion date is December 2014.
Location: Hebei, China
Trial design: Safety and efficacy
Status: Recruiting
Find out more